Brodalumab Beats Stelara in Psoriasis Trial

Share this content:
Brodalumab Beats Stelara in Psoriasis Trial, Sponsors Say
Brodalumab Beats Stelara in Psoriasis Trial, Sponsors Say
Brodalumab, an investigational monoclonal antibody drug targeting the interleukin-17 pathway, was superior both to placebo and to the current drug ustekinumab (Stelara) in a phase III trial called AMAGINE-3 in psoriasis patients, its developers said Tuesday. On a secondary efficacy endpoint, 75% reduction in disease severity according to the Psoriasis Area Severity Index (PASI), both brodalumab regimens were significantly superior to placebo.
READ FULL ARTICLE From Medical Page Today
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »